Telos Capital Management Inc. Sells 225 Shares of Amgen Inc. (NASDAQ:AMGN)

Telos Capital Management Inc. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,500 shares of the medical research company’s stock after selling 225 shares during the period. Telos Capital Management Inc.’s holdings in Amgen were worth $7,057,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after purchasing an additional 165,636 shares in the last quarter. Morgan Stanley grew its position in Amgen by 12.9% during the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after buying an additional 1,523,665 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Amgen by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after acquiring an additional 94,565 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after acquiring an additional 7,532,031 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after acquiring an additional 255,463 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.1 %

Shares of Amgen stock traded up $0.27 on Wednesday, hitting $265.91. 1,235,404 shares of the company’s stock traded hands, compared to its average volume of 2,849,470. The company has a fifty day moving average of $278.62 and a two-hundred day moving average of $281.49. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a market capitalization of $142.51 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.47 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.09 earnings per share. As a group, sell-side analysts expect that Amgen Inc. will post 19.47 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Raymond James assumed coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Truist Financial reiterated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Oppenheimer restated an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. Finally, Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.